These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 4138250)
61. [Etiology of Basedow's disease]. Kumahara U; Fukuchi M Horumon To Rinsho; 1967 Oct; 15(10):834-40. PubMed ID: 4870889 [No Abstract] [Full Text] [Related]
62. Four controversies about the cause of hyperthyroidism. Munro DS; Humphries H; Hardisty CA; Brown Y; Hanford L Lancet; 1979 Aug; 2(8136):247-8. PubMed ID: 89351 [No Abstract] [Full Text] [Related]
63. The eye changes of Graves' disease: overview. Werner SC Mayo Clin Proc; 1972 Dec; 47(12):969-74. PubMed ID: 4564711 [No Abstract] [Full Text] [Related]
64. [Effect of iodinization on some properties of LATS and antithyroid antibodies]. Romaldini JH; Pinchera A; Fenzi GF; Grasso L; Raccis E; Mariotti S; Baschieri L Folia Endocrinol; 1974 Feb; 27(1):110-6. PubMed ID: 4549507 [No Abstract] [Full Text] [Related]
65. Do heat shock proteins play a role in Graves' disease? Heat shock protein-specific T-cells from Graves' disease thyroids do not recognize thyroid epithelial cells. Trieb K; Sztankay A; Hermann M; Gratzl R; Szabo J; Jindal S; Grubeck-Loebenstein B J Clin Endocrinol Metab; 1993 Aug; 77(2):528-35. PubMed ID: 8345059 [TBL] [Abstract][Full Text] [Related]
66. [Etiopathogenesis of thyrotoxicosis]. de Medeiros Neto GA Rev Paul Med; 1967 Jan; 70(1):48-52. PubMed ID: 5631892 [No Abstract] [Full Text] [Related]
67. [The thyroid gland and autoimmunity]. Fukase M; Torizuka K; Mori T; Morita R; Sakurami T Saishin Igaku; 1967 Jul; 22(7):1411-27. PubMed ID: 4868905 [No Abstract] [Full Text] [Related]
71. Long-acting thyroid stimulator protector assay as a basis for identification of subgroups of Graves' ophthalmopathy. Solomon DH; Chopra IJ; Chopra U; Smith F Trans Assoc Am Physicians; 1976; 89():159-70. PubMed ID: 828344 [No Abstract] [Full Text] [Related]
72. The pathogenesis of hyperthyroidism. McKenzie JM Triangle; 1969; 9(1):2-8. PubMed ID: 5820145 [No Abstract] [Full Text] [Related]
73. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease. Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367 [TBL] [Abstract][Full Text] [Related]
74. Management of the active severe eye changes of Graves' disease. Werner SC Trans Am Acad Ophthalmol Otolaryngol; 1967; 71(4):631-7. PubMed ID: 6072401 [No Abstract] [Full Text] [Related]
75. Concepts of pathogenesis of Graves' disease. Solomon DH; Kleeman KE Adv Intern Med; 1977; 22():273-99. PubMed ID: 402796 [No Abstract] [Full Text] [Related]
76. Long-acting thyroid stimulator and exophthalmos. Burke G Ann Intern Med; 1969 May; 70(5):1045-6. PubMed ID: 4181434 [No Abstract] [Full Text] [Related]